ClinicalTrials.gg

Program

Methoxsalen

Also written as “methoxsalen”, “ECP Methoxsalen” and “Methoxsalen +ECP”.

Its studies are mostly in Graft vs Host Disease · Colitis · Melanoma · Bronchiolitis Obliterans Syndrome · Crohn Disease, led by 4 companies.

Furthest: phase 3, since Feb 5, 20039 company-led studies, 1 open or runningNext primary completion: Dec 2028 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Keenova Therapeutics50 open or runningphase 2since Feb 5, 2003Feb 5, 2003none ahead
Therakos21 open or runningphase 2since Oct 15, 2024Oct 15, 2024Dec 2028phase 2 · NCT07619898
Therakos10 open or runningno phasesince Nov 2, 1999Nov 2, 1999none ahead
Therakos, Inc., a Mallinckrodt10 open or runningphase 3since Aug 13, 2015Aug 13, 2015none ahead

Also a collaborator on its studies: parexel and icon-plc.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Nov 2, 1999First study: no phase study in HIV InfectionsNew to TherakosTherakos · NCT00002011 · United States
  2. Feb 5, 2003Keenova Therapeutics's first studies: 2 phase 2 studies in Graft vs Host DiseaseNew to Keenova TherapeuticsKeenova Therapeutics · NCT00054613, NCT00054600
  3. Sep 13, 20052 phase 2 studiesKeenova Therapeutics · NCT00221026, NCT00221000
  4. Jun 22, 2011Early phase 1 study in Bronchiolitis Obliterans SyndromeKeenova Therapeutics · NCT01380535 · 60 enrolled · United States, Austria, France and more
  5. Aug 13, 2015Therakos, Inc., a Mallinckrodt's first study: phase 3 study in Steroid Refractory Acute Graft Versus Host DiseaseNew to Therakos, Inc., a MallinckrodtTherakos, Inc., a Mallinckrodt · NCT02524847 · 29 enrolled · United States, Austria, France and more
  6. Oct 15, 2024Therakos's first study: phase 2 study in MelanomaNew to TherakosTherakos · NCT06646016 · United States
  7. May 19, 2026Phase 2 study in ColitisTherakos · NCT07619898 · 112 planned

Ahead

  1. Dec 2028Primary completion: phase 2 study in ColitisTherakos · NCT07619898

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 9 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07619898Colitis2Not yet recruitingTherakosDec 2028112
NCT06646016Melanoma · United States2WithdrawnTherakosFeb 6, 20260
NCT02524847Steroid Refractory Acute Graft Versus Host Disease · United States, Austria, France and more3TerminatedTherakos, Inc., a MallinckrodtJul 16, 201929
NCT01380535Bronchiolitis Obliterans Syndrome · United States, Austria, France and moreEarly 1CompletedKeenova TherapeuticsMar 201560
NCT00221026Crohn Disease · United States, Austria, Belgium and more2CompletedKeenova TherapeuticsJun 200625
NCT00221000Arthritis, Rheumatoid · United States, Australia, Austria and more2CompletedKeenova TherapeuticsOct 200686
NCT00054613Graft vs Host Disease · United States, Australia, Austria and more2CompletedKeenova Therapeutics72
NCT00054600Graft vs Host Disease · United States, Australia, Brazil and more2CompletedKeenova Therapeutics60
NCT00002011HIV Infections · United States–CompletedTherakos

How it is read

Names in the registry

  • “Methoxsalen”, 6 entries
  • “methoxsalen”, 1 entry
  • “ECP Methoxsalen”, 1 entry
  • “Methoxsalen +ECP”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.